A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
Completed · Phase 2 · NCT00002086
Conditions: HIV Infections
At a glance
- Research payments reported, 2025
- $3,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 256
About the trial
- Sponsor
- Glaxo Wellcome
- Tested
- Zidovudine (drug), Zalcitabine (drug), Interferon alfa-n1 (drug)
- Results posted
- Not yet
Primary: To determine whether the combination of zidovudine/zalcitabine/interferon alfa-n1 (Retrovir/HIVID/Wellferon) can produce complete responses (i.e., CD4 counts return to \>= 800 cells/mm3 for more than 24 weeks) in patients with virus sensitive to all three agents. To determine the antiviral effect of the combination therapies as evidenced by measures of quantitative viral load performed at select study centers only. Secondary: To determine the effectiveness of Retrovir/HIVID and Retrovir/HIVID/Wellferon in maintaining or increasing CD4 counts and preventing disease progression as evidenced by the development of an AIDS-defining indicator disease. To determine the effect of these r…
From ClinicalTrials.gov, last updated 2005-06-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3,000 in research payments for this study in 2025 (1 payments).
Products named: Qulipta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Grace Ford MD PC $3,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.